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Abstract We have developed a new synthetic method for the synthe-
sis of aziridines using Chloramine-T as an effective reagent in the pres-
ence of NH2OH·HCl and NaIO4. We found that the same combination of
NH2OH·HCl and NaIO4 is also very effective for nucleophilic ring open-
ing of aziridines.
Key words aziridines, difunctionalization, aminoiodide, in situ gener-
ated iodine, room temperature
The synthetic utility of aziridines, which are strained-
ring, nitrogen-containing heterocycles, lies in the fact that
the ring can be opened up with a broad range of nucleo-
philes to produce 1,2-difunctional products.1 This scaffold
is incorporated in biologically active molecules such as the
mitomycins, azinomycins, ficellomycin, the miraziridines,
and the azicemicins (Figure 1).2
Chemistry based on ring opening of aziridines has been
used for a wide range of synthetic applications3 to produce
vicinal diamines and aminols that are key motifs in medici-
nal chemistry.4 Many biologically active compounds such as
amino acids, β-lactam antibiotics and alkaloids can be de-
rived from aziridines.5 In addition, ring-opened 1,2-difunc-
tional derivatives of aziridines provide excellent precursors
for construction of β-aminosulfides, aminophosphonates,
and other nitrogen-containing compounds6 that are not
easily accessible by other means.
Numerous protocols have been realized for the synthe-
sis of aziridines and fused analogues.7 These synthetic pro-
tocols mainly rely on transfer of a suitable nitrogen source
to olefins, transfer of a suitable carbon source to imines and
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N. C. Ghosal et al. PaperSyn Openintramolecular cyclization of amine derivatives.8 Various
catalytic9 and non-catalytic10 routes have been established
for the direct aziridination of alkenes, some of which de-
scribe the use of halogenated compounds.11 In particular,
chloramine-T12 and bromamine-T13 have been used as the
nitrogen source for the aziridination of alkenes.
Similarly, there is a range of methods in the literature
for ring opening of aziridines with various nucleophiles14 in
the presence Lewis acid15 or Lewis base16 catalysts and
transition metals.17
Herein, we wish to report an interesting observation
where the same reagent combination has been used for the
construction as well as ring opening of the aziridine ring. In
a continuation of our research for development of new
methodologies in organic synthesis, we have observed a
novel reagent combination for the selective oxidation of al-
cohols to carbonyl compounds.18 We have successfully pre-
pared β-iodo-β'-hydroxyethers, β-iodoethers, β-iodohy-
drins, and β-iodoacetoxy compounds19a and 1,2-diiodocar-
bonyl compounds19b using the same reagent combination in
different reaction media. Inspired by these results, we
planned to apply this combination to the synthesis as well
as ring opening of aziridines.
In addition, we have recently developed an efficient
method for the regioselective ring-opening of aziridines by
various nucleophiles under mild and solvent-free condi-
tions by using a zwitterionic-type molten salt.20 As a part of
our ongoing studies on the chemistry of aziridines,21 we be-
came interested in using the same reagent combination for
the synthesis and ring-opening of aziridines. Our method
involves the reaction of olefins with a combination of hy-
droxylamine hydrochloride and sodium periodate in the
presence of Chloramine-T/K2CO3 in dichloromethane–ace-
tonitrile as solvent, wherein we observed that aziridine
ring-opening took place regioselectively (Scheme 1).
Initially, optimization of the reaction conditions was
undertaken by varying the amount of NaIO4 and NH2OH·
HCl, Chloramine-T, K2CO3 and solvent as shown in Table 1
using styrene (1a) as the model substrate. All reactions
were carried out on 1 mmol scale at room temperature.
When we employed 1 equiv of NaIO4, NH2OH·HCl, Chlora-
mine-T, and K2CO3 in 5 mL of CH2Cl2 no desired product (2a)
was observed after 14 h (Table 1, entry 1). Increasing the
amount of all of reagents equally gave no reaction (entries
2–6). Use of a mixture of CH2Cl2 and acetonitrile (1:1 v/v) as
solvent afforded 2a in 52% yield in the presence of 1 equiv
of all reagents (entry 7), indicating that the binary solvent
system might play an important role in this conversion. By
increasing the amount of NH2OH·HCl from 1 to 1.5 equiv
the yield of (2a) was increased to 76% (entry 8). Further in-
creases in the amounts of all reagents in different ratios did
not improve yields significantly (entries 9–11) but decreas-
ing the amounts led to decreased yields (entries 12–14). In
the absence of Chloramine-T or K2CO3 the reaction did not
proceed (entries 15 and 16). We have also examined the
role of solvent for this reaction and found that only a mix-
ture of dichloromethane and acetonitrile was effective; the
reaction did not proceed at all when only CH2Cl2 or acetoni-
trile was used (entries 4 and 17). No product, or only a neg-
ligible amount (20%) of product, was obtained when we
used solvents such as toluene, dichloroethane or dimethyl
sulfoxide (entries 18–22). Finally, we chose the optimized
reaction conditions using 1 equiv of NaIO4, 1.5 equiv of
NH2OH·HCl, 1 equiv of Chloramine-T and 1 equiv of K2CO3
with respect to the 1 equiv of styrene (1a) in 5 mL of CH2Cl2
and acetonitrile (1:1 v/v) at room temperature for 14 h (en-
try 8).
With the optimized reaction conditions in hand, the
substrate scope of this protocol was investigated; the re-
sults are presented in Table 2. At first, our attention was fo-
cused on the use of olefinic substrates with various substi-
tutions. Styrenes possessing an electron-withdrawing halo-
gen group on the aromatic ring showed good efficiency
(2a–e), with the 4-chloro- and 2-chloro-substituted sty-
renes giving the corresponding 2b and 2d in 70% and 71%
yields, respectively. Other halogen substituents equally af-
forded the desired products with satisfactory yields (2c and
2e). In addition, different α,β-unsaturated carbonyl com-
pounds were also examined and it was found that the
method was effective for chalcone as well as substituted
chalcones to produce the corresponding aziridines (2f–j).
Chalcones with halogens on the aromatic ring gave the de-
sired products efficiently (2g, 2h, 2i and 2j) under the opti-
mized reaction conditions. Known compounds were char-
acterized by spectroscopic analysis and novel compounds
by both spectroscopic analysis and elemental analysis. A
single crystal X-ray analysis of 2f was performed to confirm
the structure (Figure 2).22
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N. C. Ghosal et al. PaperSyn OpenFigure 2  The single crystal X-ray diffraction structure of compound 2f
We then turned our attention to the regioselective ring-
opening of the synthesized aziridines 2. We thus explored
the possibility of applying the general tendency of aziri-
dines towards ring opening using a NaIO4 and NH2OH·HCl
combination as an iodine source to obtain the iodinated
ring opening products. Gratifyingly, the corresponding
ring-opening products 3 were obtained regioselectively in
good yields; the results are summarized in Table 3. All the
synthesized aziridines gave the desired ring-opening prod-
ucts efficiently. For the ring-opening reaction we used only
acetonitrile as solvent. We did not feel the need to spend
much time on optimization of this ring opening step but
found no need to use dichloromethane. We did not observe
any by-products for any substrate, all of which reacted with
high yield and regioselectivity under the protocol.
Table 1  Optimization of the Reaction Conditionsa
Entry NaIO4 (equiv) NH2OH·HCl (equiv) Chloramine-T (equiv) K2CO3 (equiv) Solvent (5 mL) Yield (%)b
1 1 1 1 1 CH2Cl2 0
2 1 1 2 1 CH2Cl2 0
3 1 1 1 2 CH2Cl2 0
4 1 1.5 1 1 CH2Cl2 0
5 1 2 1 1 CH2Cl2 0
6 1.5 1 1 1 CH2Cl2 0
7 1 1 1 1 CH2Cl2–MeCN (1:1) 52
8 1 1.5 1 1 CH2Cl2–MeCN (1:1) 76
9 1.5 1.5 1 1 CH2Cl2–MeCN (1:1) 72
10 1 1.5 1 2 CH2Cl2–MeCN (1:1) 71
11 1 1.5 2 1 CH2Cl2–MeCN (1:1) 72
12 1 1.5 1 0.5 CH2Cl2–MeCN (1:1) 58
13 1 1.5 0.5 1 CH2Cl2–MeCN (1:1) 56
14 0.5 1.5 1 1 CH2Cl2–MeCN (1:1) 35
15 1 1.5 – 1 CH2Cl2–MeCN (1:1) 0
16 1 1.5 1 – CH2Cl2–MeCN (1:1) 0
17 1 1.5 1 1 MeCN 0
18 1 1.5 1 1 toluene 0
19 1 1.5 1 1 1,2-dichloroethane (DCE) 0
20 1 1.5 1 1 DCE–MeCN (1:1) 20
21 1 1.5 1 1 DMSO 0
22 1 1.5 1 1 DMSO–MeCN (1:1) 0
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N. C. Ghosal et al. PaperSyn OpenTable 2  Substrates Scope for the Synthesis of Aziridinesa











a All reactions were performed on 1 mmol scale in the presence of NaIO4 (1 mmol), Chloramine-T (1 mmol), K2CO3 (1 mmol) and NH2OH·HCl (1.5 mmol) in 5 mL 
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N. C. Ghosal et al. PaperSyn OpenTable 3  Regioselective Ring-Opening of the Synthesized Aziridinesa






6 12 83 (syn/anti 1:4)
7 12 82 (syn/anti 1:5)
8 12 74 (syn/anti 1:3)


































































3iGeorg Thieme Verlag  Stuttgart · New York — SynOpen 2017, 1, 15–23
20
N. C. Ghosal et al. PaperSyn OpenTable 3 (continued)
Based on literature7o,11d,23 and on our previous re-
ports18,19 we assume that the pathway for the aziridination
is as depicted in Scheme 2. The iodine produced in situ acts
as a source for the generation of I+ ion. Initially, I+ may react
with the Chloramine-T to produce I, which can react with
the alkene to afford the iodonium ion II. Then the reaction
of the TsNCl− with iodonium ion II gives β-iodo-N-chloro-N-
toluenesulfonamide III. Finally, cyclization of III in the pres-
ence of base forms the desired aziridine and species I is re-
generated. In the second step, nucleophilic ring opening of
the aziridine by iodine affords the ring opening product un-
der the same reaction conditions.
Scheme 2  Proposed mechanistic pathway
In summary, we have developed a simple and general
method for the synthesis of aziridines and their ring-open-
ing products at room temperature by using a combination
of NH2OH·HCl and NaIO4 as iodine source. The advantages
of this present protocol are the use of in situ generated io-
dine, mild reaction conditions, and high yields. These fea-
tures render this protocol facile and suitable to create a di-
versified library of aziridines and their ring-opening com-
pounds.
Synthesis of 2; General Procedure
A mixture of alkene (1 mmol), NaIO4 (1 mmol, 213 mg), and Chlora-
mine-T (1 mmol, 228 mg) was dissolved in CH2Cl2 (2.5 mL) in a round-
bottomed flask at r.t. and then NH2OH·HCl (1.5 mmol, 104 mg) was
added portion-wise over 5 min. The reaction mixture was stirred for
1 h at r.t. and then K2CO3 (1 mmol, 138 mg) and acetonitrile (2.5 mL)
were added and the mixture stirred for further 12 h. After completion
(TLC), the reaction mixture was diluted with a 1:1 mixture of wa-
ter/EtOAc (10 mL) and washed with 10% (w/v) Na2S2O3 (3 × 5 mL) fol-
lowed by brine (1 × 10 mL). The organic layer was dried over anhy-
drous Na2SO4 and filtered. Evaporation of solvent furnished the crude
product, which was subjected to column chromatography using
EtOAc–petroleum ether (1:15) as eluent to obtain the analytically
pure product.
Synthesis of 3; General Procedure
To a mixture of aziridine 2 (1 mmol), NaIO4 (1 mmol, 213 mg), and
acetonitrile (5 mL) in a round-bottomed flask at r.t., was added
NH2OH·HCl (1.5 mmol, 104 mg) portion-wise over 5 min. The reac-
tion mixture was then stirred at r.t. until completion (TLC). The reac-
tion mixture was diluted with a 1:1 mixture of water/EtOAc (10 mL)
and washed with 10% (w/v) Na2S2O3 (3 × 5 mL) followed by brine
(1 × 10 mL). The organic layer was dried over anhydrous Na2SO4 and
filtered. Evaporation of solvent furnished the crude product, which
was subjected to column chromatography using EtOAc–petroleum
ether (1:15) as eluent to obtain the analytically pure product.
2-Phenyl-1-tosylaziridine (2a)7l
Yellowish-white solid (208 mg, yield 76%); mp 86–88 °C.
1H NMR (CDCl3, 400 MHz): δ = 7.78 (d, J = 8.4 Hz, 2 H), 7.25–7.11 (m,
7 H), 3.70–3.67 (m, 1 H), 2.89 (d, J = 7.2 Hz, 1 H), 2.33 (s, 3 H), 2.30 (d,
J = 4.4 Hz, 1 H).
2-(4-Chlorophenyl)-1-tosylaziridine (2b)7l
White solid (215 mg, yield 70%); mp 108–110 °C. 1H NMR (CDCl3, 400
MHz): δ = 7.84 (d, J = 8.4 Hz, 2 H), 7.33 (d, J = 6.8 Hz, 2 H), 7.25 (d, J =
8.4 Hz, 2 H), 7.14 (d, J = 8.8 Hz, 2 H), 3.74–3.71 (m, 1 H), 2.96 (d, J =
7.2 Hz, 1 H), 2.42 (s, 3 H), 2.33 (d, J = 4.4 Hz, 1 H).
10 12 78 (syn/anti 1:3)
a All reactions were performed on 1 mmol scale in the presence of NaIO4 (1 mmol) and NH2OH·HCl (1.5 mmol) in 5 mL of MeCN at room temperature.
b Isolated yield.





























6 NaIO4  + 14 NH2OH·HCl 3 I2 + 14 NO + 24 H2O + 6 NaCl + 8 HCl
For aziridination:
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White solid (254 mg, yield 72%); mp 123–125 °C. 1H NMR (CDCl3, 400
MHz): δ = 7.75 (d, J = 8.0 Hz, 2 H), 7.30 (d, J = 8.4 Hz, 2 H), 7.23 (d, J =
8.0 Hz, 2 H), 6.98 (d, J = 8.4 Hz, 2 H), 3.63–3.60 (m, 1 H), 2.87 (d, J =
7.2 Hz, 1 H), 2.32 (s, 3 H), 2.24 (d, J = 4.4 Hz, 1 H).
2-(2-Chlorophenyl)-1-tosylaziridine (2d)
Gummy mass (219 mg, yield 71%); 1H NMR (CDCl3, 400 MHz): δ = 7.90
(d, J = 8.0 Hz, 2 H), 7.35–7.16 (m, 6 H), 4.06–4.03 (m, 1 H), 3.02 (d, J =
7.2 Hz, 1 H), 2.42 (s, 3 H), 2.29 (d, J = 4.4 Hz, 1 H). 13C NMR (CDCl3, 100
MHz): δ = 144.8, 134.5, 133.7, 133.0, 129.8, 129.3, 129.1, 128.0, 127.4,
127.0, 38.8, 35.5, 21.6. Anal. Calcd for C15H14ClNO2S: C, 58.53; H, 4.58;
N, 4.55%. Found: C, 58.56; H, 4.62; N, 4.59%.
2-(3-Fluorophenyl)-1-tosylaziridine (2e)
Yellowish-white solid (216 mg, yield 74%); mp 82–84 °C. 1H NMR
(CDCl3, 400 MHz): δ = 7.78 (d, J = 8.4 Hz, 2 H), 7.27–7.15 (m, 3 H),
6.96–6.81 (m, 3 H), 3.69–3.66 (m, 1 H), 2.90 (d, J = 7.2 Hz, 1 H), 2.36 (s,
3 H), 2.27 (d, J = 4.4 Hz, 1 H). 13C NMR (CDCl3, 100 MHz): δ = 163.0 (d,
1JC–F = 245 Hz), 145.0, 137.9, 137.8, 134.9, 130.3 (d, 4JC–F = 8 Hz), 129.9,
128.1, 122.6 (d, 3JC–F = 3 Hz), 115.5, 115.3, 113.5 (d, 2JC–F = 22 Hz), 40.4,
36.3, 21.8. Anal. Calcd for C15H14FNO2S: C, 61.84; H, 4.84; N, 4.81%.
Found: C, 61.80; H, 4.89; N, 4.87%.
Phenyl(3-phenyl-1-tosylaziridin-2-yl)methanone (2f)11d
White solid (272 mg, yield 72%); mp 139–141 °C. 1H NMR (CDCl3, 400
MHz): δ = 8.06–8.04 (m, 2 H), 7.72 (d, J = 8.4 Hz, 2 H), 7.64–7.60 (m,
1 H), 7.50–7.46 (m, 2 H), 7.34 (s, 5 H), 7.26–7.21 (m, 2 H), 4.52 (d, J =
4.0 Hz, 1 H), 4.29 (d, J = 4.0 Hz, 1 H), 2.39 (s, 3 H).
(3-(4-Chlorophenyl)-1-tosylaziridin-2-yl)(phenyl)methanone 
(2g)11d
White solid (284 mg, yield 69%); mp 148–150 °C. 1H NMR (CDCl3, 400
MHz): δ = 8.03 (d, J = 8.0 Hz, 2 H), 7.70 (d, J = 7.6 Hz, 2 H), 7.64–7.60
(m, 1 H), 7.50–7.46 (m, 3 H), 7.30–7.22 (m, 5 H), 4.48 (d, J = 4.0 Hz,
1 H), 4.24 (d, J = 4.0 Hz, 1 H), 2.40 (s, 3 H).
(3-(4-Fluorophenyl)-1-tosylaziridin-2-yl)(phenyl)methanone (2h)
Gray solid (261 mg, yield 66%); mp 105–107 °C. 1H NMR (CDCl3, 400
MHz): δ = 8.05–8.02 (m, 2 H), 7.70 (d, J = 8.4 Hz, 2 H), 7.64–7.60 (m,
1 H), 7.50–7.46 (m, 2 H), 7.35–7.31 (m, 2 H), 7.26–7.22 (m, 2 H), 7.04–
7.00 (m, 2 H), 4.49 (d, J = 4.0 Hz, 1 H), 4.28 (d, J = 4.4 Hz, 1 H), 2.40 (s,
3 H). 13C NMR (CDCl3, 100 MHz): δ = 190.3, 163.1 (d, 1JC–F = 246 Hz),
144.6, 136.6, 136.0, 134.3, 129.7, 129.6 (d, 4JC–F = 8 Hz), 129.0 (d, 3JC–F =
9 Hz), 128.8, 128.7, 127.8, 115.8 (d, 2JC–F = 21 Hz), 50.1, 46.9, 21.7.
Anal. Calcd for C22H18FNO3S: C, 66.82; H, 4.59; N, 3.54%. Found: C,
66.86; H, 4.65; N, 3.49%.
(4-Chlorophenyl)(3-phenyl-1-tosylaziridin-2-yl)methanone (2i)
White solid (280 mg, yield 68%); mp 144–146 °C. 1H NMR (CDCl3, 400
MHz): δ = 7.99 (d, J = 8.4 Hz, 2 H), 7.71 (d, J = 8.4 Hz, 2 H), 7.45 (d, J =
8.4 Hz, 2 H), 7.35–7.33 (m, 4 H), 7.26–7.23 (m, 2 H), 7.17 (s, 1 H), 4.53
(d, J = 4.4 Hz, 1 H), 4.18 (d, J = 4.0 Hz, 1 H), 2.41 (s, 3 H). 13C NMR
(CDCl3, 100 MHz): δ = 189.6, 144.9, 141.1, 136.7, 134.7, 133.2, 130.7,
129.9, 129.5, 129.3, 129.0, 128.0, 127.7, 50.6, 47.5, 21.9. Anal. Calcd




Yellowish-white solid (279 mg, yield 65%); mp 143–145 °C. 1H NMR
(CDCl3, 400 MHz): δ = 7.99–7.97 (m, 2 H), 7.69 (d, J = 8.4 Hz, 2 H),
7.46–7.44 (m, 2 H), 7.32–7.28 (m, 2 H), 7.26–7.23 (m, 2 H), 7.04–7.00
(m, 2 H), 4.49 (d, J = 4.0 Hz, 1 H), 4.17 (d, J = 4.4 Hz, 1 H), 2.41 (s, 3 H).
13C NMR (CDCl3, 100 MHz): δ = 189.2, 163.1 (d, 1JC–F = 247 Hz), 144.8,
140.9, 136.4, 134.4, 130.5, 129.7, 129.5 (d, 4JC–F = 8 Hz), 129.3, 128.7
(d, 3JC–F = 3 Hz), 127.8, 115.8 (d, 2JC–F = 22 Hz), 50.2, 46.6, 21.7. Anal.
Calcd for C22H17ClFNO3S: C, 61.47; H, 3.99; N, 3.26%. Found: C, 61.54;
H, 4.04; N, 3.21%.
N-(2-Iodo-2-phenylethyl)-4-methylbenzenesulfonamide (3a)
Yellowish-white solid (360 mg, yield 90%); mp 79–81 °C. 1H NMR
(CDCl3, 400 MHz): δ = 7.64 (d, J = 8.4 Hz, 2 H), 7.30–7.17 (m, 7 H), 4.98
(bs, 1 H), 4.80–4.77 (m, 1 H), 3.42–3.29 (m, 2 H), 2.35 (s, 3 H). 13C
NMR (CDCl3, 100 MHz): δ = 143.9, 137.9, 137.0, 130.0, 129.2, 129.0,
127.3, 127.1, 61.7, 50.4, 21.6. Anal. Calcd for C15H16INO2S: C, 44.90; H,
4.02; N, 3.49%. Found C, 44.86; H, 4.03; N, 3.38%.
N-(2-(4-Chlorophenyl)-2-iodoethyl)-4-methylbenzenesulfon-
amide (3b)
Gray solid (357 mg, yield 82%); mp 100–102 °C. 1H NMR (CDCl3, 400
MHz): δ = 7.65–7.62 (m, 2 H), 7.25–7.14 (m, 6 H), 4.87 (bs, 1 H), 4.81–
4.78 (m, 1 H), 3.37–3.32 (m, 2 H), 2.37 (s, 3 H). 13C NMR (CDCl3, 100
MHz): δ = 144.1, 137.0, 136.5, 135.1, 130.0, 129.2, 128.8, 127.1, 60.9,
50.4, 21.7. Anal. Calcd for C15H15ClINO2S: C, 41.35; H, 3.47; N, 3.21%.
Found C, 41.28; H, 3.40; N, 3.25%.
N-(2-(4-Bromophenyl)-2-iodoethyl)-4-methylbenzenesulfon-
amide (3c)
White solid (408 mg, yield 85%); mp 109–111 °C. 1H NMR (CDCl3, 400
MHz): δ = 7.65 (d, J = 7.6 Hz, 2 H), 7.37 (d, J = 7.6 Hz, 2 H), 7.25 (d, J =
7.6 Hz, 2 H), 7.11 (d, J = 7.6 Hz, 2 H), 5.29–5.26 (m, 1 H), 4.83–4.80 (m,
1 H), 3.39–3.35 (m, 2 H), 2.39 (s, 3 H). 13C NMR (CDCl3, 100 MHz): δ =
144.1, 137.2, 137.0, 132.2, 130.1, 129.2, 127.2, 123.2, 60.9, 50.4, 21.8.
Anal. Calcd for C15H15BrINO2S: C, 37.52; H, 3.15; N, 2.92%. Found: C,
37.48; H, 3.09; N, 2.87%.
N-(2-(2-Chlorophenyl)-2-iodoethyl)-4-methylbenzenesulfon-
amide (3d)
Yellowish-white solid (340 mg, yield 78%); mp 84–86 °C. 1H NMR
(CDCl3, 400 MHz): δ = 7.68–7.66 (m, 2 H), 7.43–7.40 (m, 1 H), 7.28–
7.18 (m, 5 H), 5.31–5.28 (m, 1 H), 4.94–4.90 (m, 1 H), 3.55–3.49 (m,
1 H), 3.33–3.26 (m, 1 H), 2.36 (s, 3 H). 13C NMR (CDCl3, 100 MHz): δ =
143.9, 137.1, 135.3, 132.9, 130.2, 130.00, 129.98, 128.8, 127.6, 127.2,
58.1, 49.3, 21.7. Anal. Calcd for C15H15ClINO2S: C, 41.35; H, 3.47; N,
3.21%. Found: C, 41.41; H, 3.41; N, 3.26%.
N-(2-(3-Fluorophenyl)-2-iodoethyl)-4-methylbenzenesulfon-
amide (3e)
Yellowish-white solid (336 mg, yield 80%); mp 74–76 °C. 1H NMR
(CDCl3, 400 MHz): δ = 7.73–7.71 (m, 2 H), 7.33–7.26 (m, 3 H), 7.08–
6.98 (m, 3 H), 4.97 (bs, 1 H), 4.88–4.84 (m, 1 H), 3.46–3.39 (m, 2 H),
2.44 (s, 3 H). 13C NMR (CDCl3, 100 MHz): δ = 162.9 (d, 1JC–F = 245 Hz),
144.1, 140.4, 140.3, 137.0, 130.6 (d, 4JC–F = 9 Hz), 130.0, 127.1, 123.1
(d, 3JC–F = 3 Hz), 116.3, 116.1, 114.5 (d, 2JC–F = 24 Hz), 60.9, 50.4, 21.7.
Anal. Calcd for C15H15FINO2S: C, 42.97; H, 3.61; N, 3.34%. Found: C,
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fonamide (3f)
Mixture of diastereomers [syn(A)/anti(B) = 1:4]; yellowish-white solid
(421 mg, yield 83%); mp 114–116 °C. 1H NMR (CDCl3, 400 MHz): δ =
7.67–7.63 (m, 2.5 H, 2A+2B), 7.51–7.47 (m, 1.2 H, 1A+1B), 7.45–7.42
(m, 2 H, 2B), 7.38–7.36 (m, 0.5 H, 2A), 7.34–7.30 (m, 2.4 H, 2A+2B),
7.20–7.17 (m, 2.4 H, 2A+2B), 7.16–7.13 (m, 3.7 H, 3A+3B), 7.00–6.94
(m, 2.5 H, 2A+2B), 5.81–5.79 (m, 0.2 H, 1A), 5.60–5.57 (m, 1 H, 1B),
5.35–5.31 (m, 1 H, 1B), 5.24–5.21 (m, 0.2 H, 1A), 5.10 (d, J = 4.0 Hz,
0.2 H, 1A), 5.05 (d, J = 6.4 Hz, 1 H, 1B), 2.20 (s, 0.7 H, 3A), 2.18 (s, 3 H,
3B). 13C NMR (CDCl3, 100 MHz): δ = 196.2, 143.7, 136.8, 136.6, 136.1,
135.3, 134.3, 129.6, 129.1, 129.0, 128.8, 128.6, 128.0, 127.2, 62.7, 61.8,
21.5. Anal. Calcd for C22H20INO3S: C, 52.29; H, 3.99; N, 2.77%. Found:
C, 52.35; H, 4.06; N, 2.82%.
N-(3-(4-Chlorophenyl)-3-iodo-1-oxo-1-phenylpropan-2-yl)-4-
methylbenzenesulfonamide (3g)
Mixture of diastereomers [syn(A)/anti(B)= 1:5]; gray solid (442 mg,
yield 82%); mp 130–132 °C. 1H NMR (CDCl3, 400 MHz): δ = 7.81–7.77
(m, 2.4 H, 2A+2B), 7.62–7.59 (m, 1.2 H, 1A+1B), 7.51–7.42 (m, 4.8 H,
4A+4B), 7.30 (d, J = 8.4 Hz, 0.4 H, 2A), 7.20–7.13 (m, 4.5 H, 2A+4B),
7.09 (d, J = 8.0 Hz, 0.4 H, 2A), 7.04 (d, J = 8.0 Hz, 2 H, 2B), 5.91 (d, J =
9.2 Hz, 0.2 H, 1A), 5.69 (d, J = 9.6 Hz, 1 H, 1B), 5.39–5.34 (m, 1 H, 1B),
5.28–5.25 (m, 0.2 H, 1A), 5.16 (d, J = 3.2 Hz, 0.2 H, 1A), 5.04 (d, J =
7.2 Hz, 1 H, 1B), 2.32 (s, 0.6 H, 3A), 2.29 (s, 3 H, 3B). 13C NMR (CDCl3,
100 MHz): δ = 196.7, 144.1, 136.9, 135.4, 135.3, 135.1, 134.6, 134.4,
129.8, 129.7, 129.4, 129.1, 128.9, 128.8, 127.3, 62.5, 61.3, 21.8. Anal.
Calcd for C22H19ClINO3S: C, 48.95; H, 3.55; N, 2.59%. Found: C, 48.98;
H, 3.52; N, 2.65%.
N-(3-(4-Fluorophenyl)-3-iodo-1-oxo-1-phenylpropan-2-yl)-4-
methylbenzenesulfonamide (3h)
Mixture of diastereomers [syn(A)/anti(B) = 1:3]; gummy mass (387
mg, yield 74%). 1H NMR (CDCl3, 400 MHz): δ = 7.79–7.74 (m, 2.7 H,
2A+2B), 7.60–7.57 (m, 1.3 H, 1A+1B), 7.55–7.53 (m, 0.6 H, 2A), 7.49–
7.47 (m, 2.3 H, 1A+2B), 7.45–7.40 (m, 2.3 H, 1A+2B), 7.38–7.34 (m,
0.6 H, 2A), 7.23–7.19 (m, 2 H, 2B), 7.07 (d, J = 8.0 Hz, 0.6 H, 2A), 7.01
(d, J = 8.0 Hz, 2 H, 2B), 6.94–6.86 (m, 2.6 H, 2A+2B), 5.99–5.97 (m,
0.3 H, 1A), 5.83–5.81 (m, 1 H, 1B), 5.40–5.36 (m, 1 H, 1B), 5.29–5.26
(m, 0.3 H, 1A), 5.17 (d, J = 4.0 Hz, 0.3 H, 1A), 5.09 (d, J = 7.2 Hz, 1 H,
1B), 2.28 (s, 0.9 H, 3A), 2.26 (s, 3 H, 3B). 13C NMR (CDCl3, 100 MHz): δ
= 196.5, 163.0 (d, 1JC–F = 246 Hz), 143.8, 136.8, 135.3, 134.3, 132.5,
132.2, 129.9 (d, 4JC–F = 9 Hz), 129.6, 129.1, 128.9 (d, 3JC–F = 7 Hz), 127.1,
115.5 (d, 2JC–F = 21 Hz), 62.3, 61.2, 21.4. Anal. Calcd for C22H19FINO3S:
C, 50.49; H, 3.66; N, 2.68%. Found: 50.43; H, 3.69; N, 2.62%.
N-(1-(4-Chlorophenyl)-3-iodo-1-oxo-3-phenylpropan-2-yl)-4-
methylbenzenesulfonamide (3i)
Mixture of diastereomers [syn(A)/anti(B) = 1:3]; gummy mass (416
mg, yield 77%). 1H NMR (CDCl3, 400 MHz): δ = 7.71–7.63 (m, 2.6 H,
2A+2B), 7.54 (d, J = 8.4 Hz, 0.6 H, 2A), 7.46 (d, J = 8.4 Hz, 2 H, 2B),
7.43–7.32 (m, 4 H, 3A+3B), 7.26–7.24 (m, 5.2 H, 4A+4B), 7.07 (d, J =
8.0 Hz, 0.6 H, 2A), 7.02 (d, J = 8.0 Hz, 2 H, 2B), 5.88 (d, J = 9.2 Hz, 0.3 H,
1A), 5.74 (d, J = 9.6 Hz, 1 H, 1B), 5.35–5.29 (m, 1 H, 1B), 5.27–5.23 (m,
0.3 H, 1A), 5.12 (d, J = 4.8 Hz, 0.3 H, 1A), 5.09 (d, J = 7.2 Hz, 1 H,1B),
2.29 (s,0.9 H, 3A), 2.28 (s, 3 H, 3B). 13C NMR (CDCl3, 100 MHz): δ =
195.8, 144.0, 141.0, 136.9, 136.4, 133.5, 130.3, 129.8, 129.4, 129.3,
128.9, 128.2, 127.3, 62.8, 61.7, 21.7. Anal. Calcd. for C22H19ClINO3S: C,
48.95; H, 3.55; N, 2.59%. Found: C, 48.98; H, 3.59; N, 2.63%.
N-(1-(4-Chlorophenyl)-3-(4-fluorophenyl)-3-iodo-1-oxopropan-
2-yl)-4-methylbenzenesulfonamide (3j)
Mixture of diastereomers [syn(A)/anti(B) = 1:3]; gummy mass (435
mg, yield 78%). 1H NMR (CDCl3, 400 MHz): δ = 7.74 (d, J = 8.4 Hz, 2 H,
2B), 7.68 (d, J = 8.4 Hz, 0.6 H, 2A), 7.53 (d, J = 8.0 Hz, 0.6 H, 2A), 7.44–
7.39 (m, 4.6 H, 2A+4B), 7.34–7.31 (m, 0.6 H, 2A), 7.26–7.20 (m, 2 H,
2B), 7.09 (d, J = 8.0 Hz, 0.6 H, 2A), 7.03 (d, J = 8.0 Hz, 2 H, 2B), 6.93–
6.87 (m, 2.6 H, 2A+2B), 5.91 (d, J = 9.6 Hz, 0.3 H, 1A), 5.78 (d, J =
9.6 Hz, 1 H, 1B), 5.31–5.27 (m, 1 H, 1B), 5.24–5.20 (m, 0.3 H, 1A), 5.13
(d, J = 4.4 Hz,0.3 H,1A), 5.02 (d, J = 7.6 Hz, 1 H, 1B), 2.30 (s, 0.9 H, 3A),
2.29 (s, 3 H, 3B). 13C NMR (CDCl3, 100 MHz): δ = 195.9, 163.0 (d, 1JC–F =
247 Hz), 143.9, 141.0, 136.7, 133.8, 132.7, 132.2 (d, 4JC–F = 3 Hz), 130.3,
129.9 (d, 3JC–F = 8 Hz), 129.6, 127.1, 115.6 (d, 2JC–F = 22 Hz), 62.2, 60.9,
21.5. Anal. Calcd for C22H18ClFINO3S: C, 47.37; H, 3.25; N, 2.51%.
Found: C, 47.41; H, 3.32; N, 2.55%.
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